
Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites. Educating physicians on a fully global scale since 2005! We make positive changes to clinical practice, with the ultimate objective of improving patient and community health. Working alongside leading medical experts, societies and industry, our mission is to provide practical, expert opinions to support best practices for busy Healthcare Professionals globally, by translating published data into easily digestible and timely updates Home of: - touchONCOLOGY - touchENDOCRINOLOGY - touchOPHTHALMOLOGY - touchNEUROLOGY - touchCARDIOLOGY - touchINFECTIOUSDISEASES - touchIMMUNOLOGY - touchRESPIRATORY - touchHAEMATOLOGY - touchDERMATOLOGY This information is intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis, or treatment recommendations.
Episodes

Wednesday Nov 10, 2021
Wednesday Nov 10, 2021
touchPANEL DISCUSSION for touchONCOLOGY
Listen as leading experts discuss the latest clinical data for emerging HER2-directed therapies and review novel therapeutic strategies and consider the implications for clinical practice.
The experts
- Dr Laura Biganzoli – Department of Oncology, Hospital of Prato, Prato, Italy
- Dr Peter Fasching – Comprehensive Cancer Center, Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
- Dr Sonia Pernas – Catalan Institute of Oncology, and Faculty of Medicine, University of Barcelona, Barcelona, Spain
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent educational grant from SeaGen. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/expanding_options_her2_advanced_breast_cancer/
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.